Takeda has proposed selling off a Shire treatment for inflammatory bowel disease when the companies merge next year, to avoid an overlap with its own drug.
Pfizer’s janus kinase (JAK) inhibitor drug Xeljanz (tofacitinib) has received expanded approval from the FDA for adults with moderately-to-severely-active ulcerative colitis.